ABSTRACT
BACKGROUND AND OBJECTIVE: To report five cases of iritis after intravitreal injection of bevacizumab. PATIENTS AND METHODS: The clinical charts of patients who received intravitreal injections of bevacizumab or ranibizumab from January 2009 to September 2011 by one physician were retrospectively reviewed. RESULTS: A total of 1,097 injections of bevacizumab and 571 of ranibizumab were administered. Five patients developed acute anterior uveitis and presented with severe pain, photophobia, conjunctival injection, and anterior chamber reaction 2 to 24 hours after intravitreal injection of bevacizumab. All five patients were treated with topical corticosteroids with rapid resolution of the inflammation. CONCLUSION: Although uncommon, acute iritis is a complication of intravitreal injection of bevacizumab.
Subject(s)
Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Iritis/chemically induced , Acute Disease , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized/therapeutic use , Bevacizumab , Conjunctivitis/chemically induced , Conjunctivitis/diagnosis , Conjunctivitis/drug therapy , Eye Pain/chemically induced , Eye Pain/diagnosis , Eye Pain/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Incidence , Intravitreal Injections , Iritis/diagnosis , Iritis/drug therapy , Photophobia/chemically induced , Photophobia/diagnosis , Photophobia/drug therapy , Ranibizumab , Retinal Diseases/drug therapy , Retrospective Studies , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Visual AcuityABSTRACT
A 29-year-old woman with membranoproliferative glomerulonephritis type II presented with decreased vision due to choroidal neovascular membrane. She was treated with monthly intravitreal injections of bevacizumab. Although there was dramatic improvement in her vision after the third injection, it continued to improve through the ninth monthly injection. Despite recent reports of renal side effects of systemic bevacizumab, patients with preexisting renal disease treated by the authors did not demonstrate any loss of renal function 1 year after treatment.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Glomerulonephritis, Membranoproliferative/drug therapy , Retinal Neovascularization/drug therapy , Adult , Antibodies, Monoclonal, Humanized , Bevacizumab , Female , Fluorescein Angiography , Glomerulonephritis, Membranoproliferative/diagnosis , Glomerulonephritis, Membranoproliferative/physiopathology , Humans , Injections , Kidney Function Tests , Macular Edema/diagnosis , Macular Edema/drug therapy , Macular Edema/physiopathology , Ranibizumab , Retinal Neovascularization/diagnosis , Retinal Neovascularization/physiopathology , Tomography, Optical Coherence , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Visual Acuity , Vitreous BodyABSTRACT
BACKGROUND AND OBJECTIVE: Neovascular age-related macular degeneration presents a therapeutic challenge. The efficacy of pegaptanib sodium, a selective inhibitor of vascular endothelial growth factor 165, was examined as a therapeutic mainstay combined with "as needed" boosts of nonselective vascular endothelial growth factor blockade with bevacizumab or ranibizumab. PATIENTS AND METHODS: A retrospective chart review of outcomes of patients treated with pegaptanib and later boosted with bevacizumab or ranibizumab was conducted. Visual acuity, optical coherence tomography, and fluorescein angiography findings were recorded and assessed. RESULTS: During a mean follow-up of 12.1 months, an average of 7.8 injections of pegaptanib 0.3 mg, 1.4 injections of bevacizumab 1.25 mg, and 0.9 injections of ranibizumab 0.5 mg were administered to 17 eyes. In all, 47% of eyes gained 3 or more lines of visual acuity and 76% gained 0 or more lines. CONCLUSION: Pegaptanib as a mainstay of neovascular age-related macular degeneration therapy with an occasional boost of bevacizumab or ranibizumab appears to be an effective treatment option.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Aptamers, Nucleotide/therapeutic use , Choroidal Neovascularization/drug therapy , Macular Degeneration/drug therapy , Antibodies, Monoclonal, Humanized , Bevacizumab , Choroidal Neovascularization/etiology , Drug Therapy, Combination , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Injections , Macular Degeneration/complications , Male , Ranibizumab , Retrospective Studies , Tomography, Optical Coherence , Treatment Outcome , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Visual Acuity , Vitreous BodyABSTRACT
BACKGROUND: There has been a dramatic rise of type 2 diabetes mellitus (DM2) in the US pediatric population, yet the presence of retinopathy and microalbuminuria in this cohort has not yet been described. AIM: To assess the presence of retinopathy and microalbuminuria in a cohort of predominantly minority adolescents (African American and Caribbean Hispanic) with DM2. PATIENTS AND METHODS: Forty pediatric patients with DM2 were examined between July, 2001 and June, 2003 for the presence of retinopathy. Data were also collected regarding microalbuminuria, body mass index, HbA1c, and family history of DM. RESULTS: Of the 40 patients examined, one patient (2.5%) had retinopathy, whereas nine (27.3%) had microalbuminuria. CONCLUSIONS: In young predominantly minority adolescents with DM2, retinopathy is rare, while microalbuminuria is common.
